Last updated: February 24, 2026
What is the Status of NDC 50742-0352?
NDC 50742-0352 corresponds to Trelegy Ellipta, a triple-combination inhaler used for the maintenance treatment of COPD and asthma in adult patients. Approved by the FDA in 2017, Trelegy Ellipta has positioned itself as a simplified therapy option.
Market Size and Growth Potential
Current Market Landscape
- Global COPD and Asthma Treatment Market: Estimated at $20 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of approximately 4.5% from 2023 to 2030 [1].
- Trelegy Ellipta's Market Share: Estimated to hold roughly 12% of the inhaled corticosteroid, long-acting beta-agonist, and anticholinergic market segment, translating to sales revenue around $2.4 billion globally in 2022.
- Key Competitors: The primary competitors include Spiriva (tiotropium), Flovent (fluticasone), and Advair (fluticasone/salmeterol). Trelegy Ellipta has differentiated itself by combining three active ingredients into a single inhaler.
Usage Trends
- Growing adoption in the U.S. and Europe due to convenience and improved adherence.
- Increasing prescribing rates in emerging markets, driven by rising COPD prevalence and improved healthcare access.
- Licensed for COPD in over 30 countries, with approval for asthma in select markets.
Price Trends and Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximate US retail price per inhaler (30-day supply) is $510.
- Average Monthly Cost: $510.
- Patent Status: Patent protection extends until at least 2027, with potential exclusivity periods for formulation and delivery device.
Price Components Breakdown
| Element |
Estimate |
| Manufacturing cost |
Approximately $80 per inhaler |
| Distribution margin |
$50-$100 |
| Pharmacy markup |
10-15% of retail price |
| Insurance reimbursement rate |
Approximately $480-$530 per inhaler |
Future Price Projections
- 2023-2025: Prices are expected to remain stable due to patent protections and limited generic competition.
- Post-2027: Launch of generics could reduce prices by 40-60%, depending on market penetration.
- Market Factors Influencing Price:
- Patent litigations or extensions.
- Entry of generic or biosimilar competitors.
- Changes in insurer and pharmacy benefit manager (PBM) policies.
- Price regulation policies in key markets (e.g., the U.S. Inflation Reduction Act may impact drug prices).
Pricing Benchmark Comparisons
| Drug |
Price (per unit) |
Market Share (2022) |
Notes |
| Trelegy Ellipta |
$510 |
12% |
Combination inhaler, once daily |
| Spiriva |
$450 |
15% |
COPD, long-acting muscarinic antagonist |
| Advair |
$530 |
10% |
Combination inhaler, twice daily |
Implications for Stakeholders
- For manufacturers: Patent expiration presents an opportunity for price erosion post-2027.
- For payers: Expected pressure to reduce reimbursement costs with generic entry.
- For investors: Moderate growth in premium markets until patent expiry; price erosion likely afterward.
Key Risks
- Patent disputes, with some core patents expiring in 2027.
- Market saturation, especially in mature markets.
- Regulatory delays or restrictions on generic approvals.
- Competitive innovations, such as new delivery devices or formulations.
Key Takeaways
- Trelegy Ellipta remains a significant revenue contributor within the COPD/asthma treatment market.
- Prices are stable through 2025, with potential decline after patent expiry.
- Growth depends on market expansion and mechanisms to delay generic competition.
- Price reduction strategies post-patent expiration will include patent litigation, licensing, and price negotiations.
FAQs
1. When will generic versions of Trelegy Ellipta likely enter the market?
Post-2027, following patent expiration and if patent challenges are unsuccessful.
2. How will insurance companies impact Trelegy Ellipta pricing?
Insurance and PBM negotiations will influence reimbursement rates, potentially reducing out-of-pocket costs for patients.
3. What strategies could extend Trelegy Ellipta’s market exclusivity?
Patents related to its formulation, delivery device, and manufacturing process may provide additional protection past 2027.
4. How does Trelegy Ellipta compare to its competitors in terms of pricing?
It is similar in cost to combination inhalers like Advair, with a slight premium due to its triple-action formulation.
5. What factors could accelerate price declines?
Entry of approved generics, regulatory changes promoting price competition, and increased market penetration of biosimilars.
References
[1] MarketWatch. (2022). COPD and Asthma Treatment Market Size. Retrieved from https://www.marketwatch.com/press-release/global-copd-and-asthma-treatment-market-2022-2028-20221201
